Cargando…

Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model

Clonal myeloproliferation and development of bone marrow (BM) fibrosis are the major pathogenetic events in myelofibrosis (MF). The identification of novel antifibrotic strategies is of utmost importance since the effectiveness of current therapies in reverting BM fibrosis is debated. We previously...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bianchi, Elisa, Rontauroli, Sebastiano, Tavernari, Lara, Mirabile, Margherita, Pedrazzi, Francesca, Genovese, Elena, Sartini, Stefano, Dall’Ora, Massimiliano, Grisendi, Giulia, Fabbiani, Luca, Maccaferri, Monica, Carretta, Chiara, Parenti, Sandra, Fantini, Sebastian, Bartalucci, Niccolò, Calabresi, Laura, Balliu, Manjola, Guglielmelli, Paola, Potenza, Leonardo, Tagliafico, Enrico, Losi, Lorena, Dominici, Massimo, Luppi, Mario, Vannucchi, Alessandro Maria, Manfredini, Rossella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169646/ https://www.ncbi.nlm.nih.gov/pubmed/36928007 http://dx.doi.org/10.1038/s41375-023-01867-3

Ejemplares similares

P999: ERK1/2 INHIBITION REDUCES OSTEOPONTIN PLASMA LEVELS AND BONE MARROW FIBROSIS IN A MYELOFIBROSIS MOUSE MODEL
por: Rontauroli, S., et al.
Publicado: (2022)

The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis
por: Genovese, Elena, et al.
Publicado: (2022)

P987: A DIFFERENT BALANCE IN OXIDATIVE STRESS RESPONSE IN CALR AND JAK2 MUTATED MYELOFIBROSIS PATIENTS CORRELATES WITH CLINICAL OUTCOME
por: Genovese, E., et al.
Publicado: (2022)

P1003: PERIPHERAL BLOOD CYTOTOXIC T CELLS SHOW EARLY EXHAUSTED FEATURES IN MYELOFIBROSIS PATIENTS
por: Tavernari, L., et al.
Publicado: (2022)

P1000: INCREASED PLASMA LEVELS OF LNCRNAS ARE POTENTIAL PROGNOSTIC BIOMARKERS IN MYELOFIBROSIS
por: Sartini, S., et al.
Publicado: (2022)

Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis
por: Fantini, Sebastian, et al.
Publicado: (2021)

Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis
por: Parenti, Sandra, et al.
Publicado: (2021)

Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants
por: Salati, Simona, et al.
Publicado: (2019)

Genomic Analysis of Hematopoietic Stem Cell at the Single-Cell Level: Optimization of Cell Fixation and Whole Genome Amplification (WGA) Protocol
por: Carretta, Chiara, et al.
Publicado: (2020)

Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/CIP2A axis
por: Bartalucci, Niccolò, et al.
Publicado: (2017)

P983: SINGLE CELL ANALYSIS ALLOWS THE EARLY DETECTION OF LEUKEMIC CLONES IN MPN PATIENTS
por: Carretta, C., et al.
Publicado: (2022)

Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis
por: Bianchi, Elisa, et al.
Publicado: (2017)

Role of TGF‐β1/miR‐382‐5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis
por: Rossi, Chiara, et al.
Publicado: (2018)

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
por: Guglielmelli, Paola, et al.
Publicado: (2023)

Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial
por: Pardanani, A, et al.
Publicado: (2015)

miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6
por: Rontauroli, Sebastiano, et al.
Publicado: (2017)

Myelofibrosis Treatment Algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2
por: Romagnoli, Simone, et al.
Publicado: (2021)

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
por: Pacilli, Annalisa, et al.
Publicado: (2018)

Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis
por: Guglielmelli, P, et al.
Publicado: (2015)

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value
por: Vannucchi, A M, et al.
Publicado: (2014)

CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles
por: Zini, Roberta, et al.
Publicado: (2017)

Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients
por: Ruberti, S, et al.
Publicado: (2018)

Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective
por: Rontauroli, Sebastiano, et al.
Publicado: (2022)

HDAC1 controls CIP2A transcription in human colorectal cancer cells
por: Balliu, Manjola, et al.
Publicado: (2016)

Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis
por: Coltro, Giacomo, et al.
Publicado: (2022)

Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis
por: Zingariello, Maria, et al.
Publicado: (2020)

Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells
por: Guglielmelli, Paola, et al.
Publicado: (2015)

Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis
por: Guglielmelli, Paola, et al.
Publicado: (2020)

A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis
por: Carobbio, Alessandra, et al.
Publicado: (2020)

Prefibrotic myelofibrosis: treatment algorithm 2018
por: Finazzi, Guido, et al.
Publicado: (2018)

Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis
por: Martinaud, Christophe, et al.
Publicado: (2015)

mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms
por: Bogani, Costanza, et al.
Publicado: (2013)

Effectiveness of the Histone Deacetylase Inhibitor (S)-2 against LNCaP and PC3 Human Prostate Cancer Cells
por: Laurenzana, Anna, et al.
Publicado: (2013)

HDAC-inhibitor (S)-8 disrupts HDAC6-PP1 complex prompting A375 melanoma cell growth arrest and apoptosis
por: Balliu, Manjola, et al.
Publicado: (2015)

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study
por: Guglielmelli, Paola, et al.
Publicado: (2022)

Incidence of blast phase in myelofibrosis according to anemia severity
por: Mora, Barbara, et al.
Publicado: (2023)

Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis
por: Mannelli, Francesco, et al.
Publicado: (2022)

A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells
por: Calura, E, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_sm0us9lq00gvom5k4tm7r8j134